HomeCompareRPTX vs KMB

RPTX vs KMB: Dividend Comparison 2026

RPTX yields 75.47% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPTX wins by $1.31M in total portfolio value
10 years
RPTX
RPTX
● Live price
75.47%
Share price
$2.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.35M
Annual income
$375,142.22
Full RPTX calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — RPTX vs KMB

📍 RPTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPTXKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPTX + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPTX pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPTX
Annual income on $10K today (after 15% tax)
$6,415.09/yr
After 10yr DRIP, annual income (after tax)
$318,870.89/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, RPTX beats the other by $314,441.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPTX + KMB for your $10,000?

RPTX: 50%KMB: 50%
100% KMB50/50100% RPTX
Portfolio after 10yr
$699.4K
Annual income
$190,176.77/yr
Blended yield
27.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RPTX right now

RPTX
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$3.00
+13.2% upside vs current
Range: $3.00 — $3.00
Altman Z
-0.1
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPTX buys
0
KMB buys
0
No recent congressional trades found for RPTX or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPTXKMB
Forward yield75.47%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$1.35M$45.9K
Annual income after 10y$375,142.22$5,211.33
Total dividends collected$1.17M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$3.00$123.00

Year-by-year: RPTX vs KMB ($10,000, DRIP)

YearRPTX PortfolioRPTX Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$18,247$7,547.17$11,314$613.68+$6.9KRPTX
2$32,395$12,870.51$12,865$759.19+$19.5KRPTX
3$56,017$21,354.74$14,709$943.96+$41.3KRPTX
4$94,449$34,510.84$16,919$1,180.17+$77.5KRPTX
5$155,442$54,381.15$19,588$1,484.33+$135.9KRPTX
6$249,967$83,643.80$22,838$1,879.06+$227.1KRPTX
7$393,173$125,708.24$26,832$2,395.60+$366.3KRPTX
8$605,486$184,791.09$31,788$3,077.63+$573.7KRPTX
9$913,831$265,960.98$38,000$3,986.82+$875.8KRPTX
10$1,352,941$375,142.22$45,872$5,211.33+$1.31MRPTX

RPTX vs KMB: Complete Analysis 2026

RPTXStock

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Full RPTX Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this RPTX vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPTX vs SCHDRPTX vs JEPIRPTX vs ORPTX vs KORPTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.